Supernus Pharmaceuticals Completes Asset Acquisition
Ticker: SUPN · Form: 8-K · Filed: 2026-04-07T17:25:26-04:00
Sentiment: neutral
Topics: acquisition, material-definitive-agreement
Related Tickers: SUPN
TL;DR
SUPN just bought some assets, deal closed April 1st.
AI Summary
On April 1, 2026, Supernus Pharmaceuticals, Inc. entered into a material definitive agreement and completed the acquisition of assets. The filing details the completion of this acquisition, with exhibits including the agreement itself and financial statements.
Why It Matters
This acquisition signifies a strategic move by Supernus Pharmaceuticals to expand its asset portfolio, potentially impacting its future product offerings and market position.
Risk Assessment
Risk Level: medium — Acquisitions inherently carry risks related to integration, valuation, and future performance of the acquired assets.
Key Players & Entities
- Supernus Pharmaceuticals, Inc. (company) — Filer and acquirer
- 0001356576 (company) — CIK number for Supernus Pharmaceuticals, Inc.
- April 1, 2026 (date) — Period of report and effective date of acquisition
- April 7, 2026 (date) — Filing date of the 8-K
FAQ
What specific assets were acquired by Supernus Pharmaceuticals?
The filing indicates the completion of an acquisition of assets but does not specify the exact nature or details of these assets within the provided text.
What is the financial impact of this acquisition on Supernus Pharmaceuticals?
The filing mentions Item 9.01 for Financial Statements and Exhibits, suggesting financial details are available in the exhibits, but they are not detailed in the provided summary text.
Who was the seller in this asset acquisition?
The provided text does not disclose the identity of the seller in this asset acquisition.
When was the material definitive agreement entered into?
The filing states Item 1.01 covers the Entry into a Material Definitive Agreement, and the period of report is April 1, 2026, implying the agreement was likely entered into around this date.
What are the key exhibits filed with this 8-K?
The key exhibits filed include the agreement itself (EX-2.1) and XBRL financial data (EX-101).
From the Filing
EDGAR Filing Documents for 0001104659-26-040497 This page uses Javascript. Your browser either doesn't support Javascript or you have it turned off. To see this page as it is meant to appear please use a Javascript enabled browser. SEC.gov EDGAR Latest Filings Filings search tools Filing Detail SEC Home » Company Search » Current Page Form 8-K - Current report: SEC Accession No. 0001104659-26-040497 Filing Date 2026-04-07 Accepted 2026-04-07 17:25:26 Documents 12 Period of Report 2026-04-01 Items Item 1.01: Entry into a Material Definitive Agreement Item 2.01: Completion of Acquisition or Disposition of Assets Item 9.01: Financial Statements and Exhibits Interactive Data Document Format Files Seq Description Document Type Size 1 FORM 8-K tm2611273d1_8k.htm iXBRL 8-K 29738 2 EXHIBIT 2.1 tm2611273d1_ex2-1.htm EX-2.1 219277 Complete submission text file 0001104659-26-040497.txt 468922 Data Files Seq Description Document Type Size 3 XBRL TAXONOMY EXTENSION SCHEMA supn-20260401.xsd EX-101.SCH 3014 4 XBRL TAXONOMY EXTENSION LABEL LINKBASE supn-20260401_lab.xml EX-101.LAB 34239 5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE supn-20260401_pre.xml EX-101.PRE 22358 15 EXTRACTED XBRL INSTANCE DOCUMENT tm2611273d1_8k_htm.xml XML 3105 Mailing Address 9715 KEY WEST AVENUE ROCKVILLE MD 20850 Business Address 9715 KEY WEST AVENUE ROCKVILLE MD 20850 301-838-2500 SUPERNUS PHARMACEUTICALS, INC. (Filer) CIK : 0001356576 (see all company filings) EIN. : 000000000 | State of Incorp.: DE | Fiscal Year End: 1231 Type: 8-K | Act: 34 | File No.: 001-35518 | Film No.: 26845834 SIC : 2834 Pharmaceutical Preparations (CF Office: 03 Life Sciences)